Magnesium isoglycyrrhizinate

Drug Overview

Magnesium isoglycyrrhizinate (MgIG) is a hepatoprotective agent derived from licorice root, used to protect the liver from damage caused by drugs, toxins, or diseases. In oncology, doctors study it to reduce liver injury from cancer treatments like chemotherapy or targeted therapies. This compound helps ease inflammation and oxidative stress in the liver, making it a supportive option for patients facing treatment side effects. For international patients from the US and Europe, it offers a natural-based approach to manage liver health during cancer care.

MgIG is the magnesium salt of 18α-glycyrrhizic acid, a refined form of glycyrrhizin with better solubility and fewer side effects than earlier versions. It works by calming liver inflammation and aiding cell repair, which is key when cancer drugs stress the organ. Hospitals use it as an add-on therapy to help patients tolerate stronger anti-cancer treatments longer.

• Generic name: Magnesium isoglycyrrhizinate
  
• US Brand names: None approved (available as investigational or in some international formulations like MgIG injection)
  
• Drug Class: Hepatoprotective agent (glycyrrhizic acid derivative)
  
• Route of Administration: Intravenous injection or infusion; oral capsules in some regions
  
• FDA Approval Status: Not FDA approved; used in clinical practice in Asia (e.g., China, Japan) and investigational in Western markets
  

This drug supports liver function without direct anti-cancer effects, helping patients stay on treatment plans.

What Is It and How Does It Work? (Mechanism of Action)

Magnesium isoglycyrrhizinate is a bioactive compound that shields liver cells from injury by targeting inflammation, oxidative stress, and cell death pathways. It comes from glycyrrhizic acid but uses a magnesium salt form for better stability and uptake. Once in the body, MgIG enters hepatocytes and activates protective responses.

At the molecular level, MgIG scavenges reactive oxygen species (ROS) like superoxide and hydroxyl radicals, preventing lipid peroxidation in cell membranes. It boosts antioxidant enzymes such as superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase, which neutralize free radicals. This reduces oxidative damage to DNA, proteins, and mitochondria.

MgIG inhibits the TLR4/NF-κB signaling pathway. Toll-like receptor 4 (TLR4) on liver cells senses damage-associated molecular patterns (DAMPs) or lipopolysaccharides (LPS) from gut bacteria. TLR4 activation recruits MyD88, phosphorylating IRAK4 and TRAF6, which activate the IKK complex. IKK phosphorylates IκBα, freeing NF-κB p65 to enter the nucleus and transcribe pro-inflammatory genes like TNF-α, IL-1β, IL-6, and COX-2.

By binding upstream, MgIG blocks this cascade, lowering cytokine storms. It also suppresses NLRP3 inflammasome assembly. NLRP3 senses ROS or potassium efflux, oligomerizing with ASC and pro-caspase-1. Activated caspase-1 cleaves pro-IL-1β and gasdermin D, causing pyroptosis (inflammatory cell death). MgIG stabilizes NLRP3, preventing pore formation.

Additionally, MgIG modulates the JAK2/STAT3 pathway. It reduces JAK2 phosphorylation, limiting STAT3 dimerization and nuclear translocation, which curbs excess inflammation and fibrosis. In liver cells, this promotes repair via Nrf2 activation. Nrf2 dissociates from Keap1, translocates to the nucleus, and upregulates genes like HO-1 and NQO1 for detoxification.

Overall, MgIG restores liver homeostasis by balancing redox, inflammation, and apoptosis signals, protecting against chemotherapy-induced damage without interfering with anti-tumor effects.

FDA-Approved Clinical Indications

Magnesium isoglycyrrhizinate lacks FDA approval for any use. It is investigational in oncology settings.

Oncological uses (investigational):

• Prevention and treatment of chemotherapy-induced liver injury (e.g., from platinum drugs, tyrosine kinase inhibitors)
  
• Supportive care in hepatocellular carcinoma (HCC) patients with drug-induced liver toxicity
  
• Reduction of hepatic inflammation during cancer immunotherapy
  

Non-oncological uses:

• Drug-induced liver injury (anti-tuberculosis drugs, acetaminophen)
  
• Viral hepatitis (hepatitis B, C)
  
• Alcoholic and non-alcoholic fatty liver disease
  

Clinical use is common in Asia for liver support.

Dosage and Administration Protocols

MgIG is given via slow IV infusion to ensure even distribution and minimize irritation. Dosing follows hospital protocols for liver protection.

Dose adjustments:

• Renal insufficiency: Reduce by 50% if CrCl <30 mL/min; magnesium accumulation risk.
  
• Hepatic insufficiency: No adjustment needed; used for liver protection, but start low in Child-Pugh C.
  

Dilute in compatible fluids; avoid rapid boluses.

Clinical Efficacy and Research Results

Studies from 2020-2025 show MgIG reduces liver enzyme elevations during cancer treatments. In trials with anti-tuberculosis drugs (common model for DILI), MgIG lowered ALT by 40-60% and AST by 30-50% versus controls within 2 weeks.

A 2022 study on chemotherapy patients reported normalized liver function in 70% of the MgIG group versus 40% placebo group, allowing treatment continuation. Hospital stay shortened by 3-5 days. For alectinib-induced hepatotoxicity (2025 data), MgIG improved symptoms in most cases by inhibiting pyroptosis.

Generalizations indicate better tolerance to oncology drugs, with fewer dose reductions (20-30% less interruptions). No direct survival data; focus on quality of life and treatment adherence. Larger oncology-specific trials are ongoing.

Safety Profile and Side Effects

No black box warning.

Common side effects (>10%):

• Mild nausea (15-20%)
  
• Injection site pain or redness (12%)
  
• Fatigue (10-15%)
  
• Diarrhea (10%)
  

Manage nausea with small meals and antiemetics like metoclopramide. Use warm compresses for site reactions; symptoms fade quickly.

Serious adverse events:

• Hypermagnesemia (rare; <1% with proper dosing)
  
• Hypokalemia (2-5%; electrolyte shifts)
  
• Allergic reactions (rash, itching; 1-3%)
  
• Pseudoaldosteronism (edema, hypertension; <2% long-term)
  

Monitor serum magnesium and potassium weekly. For hypokalemia, supplement potassium. Stop infusion for allergies; give antihistamines. Safe profile supports broad use.

Research Areas

Limited direct links to stem cell therapies exist, but MgIG’s anti-inflammatory effects aid liver regeneration. Studies explore it with hepatocyte transplants, where reduced NF-κB enhances stem cell engraftment. In cancer, it protects the liver during immunotherapy, potentially improving outcomes.

Patient Management and Practical Recommendations

Pre-treatment tests:

• Liver function tests (ALT, AST, bilirubin, ALP)
  
• Renal function (creatinine, eGFR)
  
• Electrolytes (magnesium, potassium, sodium)
  
• Complete blood count
  
• ECG baseline
  

Precautions during treatment:

• Watch blood pressure; avoid licorice supplements.
  
• Ensure good hydration.
  
• Space from other IV drugs.
  

Do’s and Don’ts:

• Do: Report muscle weakness or swelling; eat potassium-rich foods (bananas, spinach); attend follow-up labs.
  
• Don’t: Use salt substitutes; ignore abdominal pain; exceed prescribed dose; take with antacids.
  

Legal Disclaimer

This guide provides general information about magnesium isoglycyrrhizinate and is not a substitute for professional medical advice. Consult your healthcare provider for personalized recommendations. It is not FDA approved; uses are investigational or off-label. Treatment decisions should consider individual health and approved therapies. The hospital does not endorse unapproved applications. Information may change with new research. Last reviewed March 2026.